Kuros Biosciences (XSWX:KURN) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:KURN Kuros Biosciences Ltd XSWX:KURN
64 GF Score
Price CHF20.90
GF Value CHF36.99
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Defensive Interval Ratio?

XSWX:KURN
64GF Score
Kuros Biosciences Ltd XSWX:KURN
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kuros Biosciences (XSWX:KURN) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of CHF20.90 is trading 43.5% below its estimated GF Value™ of CHF36.99. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for XSWX:KURN:

  • Defensive Interval Ratio:
  • GF Value™: CHF36.99 vs. price of CHF20.90 (43.5% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the XSWX:KURN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
64GF Score

Get the complete analysis for XSWX:KURN

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.90
Price
CHF36.99
GF Value